ISPOR - Omalizumab Is Cost-Effective Compared To Standard of Care in Uncontrolled Severe Allergic Asthma Patients

Full Text

Omalizumab Is Cost-Effective Compared To Standard of Care in Uncontrolled Severe Allergic Asthma Patients

Abstract

Authors

H Kaur S Dongare W Lijie L Alvares

Back to Volume 21, Supplemental S2

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now